logo
Plus   Neg
Share
Email

AstraZeneca: Phase III NEPTUNE Trial Of Imfinzi Fails To Meet Primary Goal

AstraZeneca plc (AZN.L,AZN) announced Wednesday final overall survival or OS results from the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer or NSCLC.

In the trial, the combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving OS, while safety and tolerability profile for the combination was consistent with previous trials.

The Phase III NEPTUNE trial was a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an anti-CTLA4 antibody, vs. standard-of-care or SoC platinum-based chemotherapy in previously-untreated Stage IV (metastatic) NSCLC patients.

The trial is being conducted in more than 200 centres across 29 countries, including the US, Europe, South and Central America, the Middle East and Asia.

The company noted that the trial was performed in an all-comers population. The primary analysis population was patients with a high tumour mutational burden or TMB, which is a measurement of the number of mutations within the genome of a tumour.

According to the company, in the primary analysis population of patients whose blood TMB was 20 or more mutations per megabase or mut/Mb, the combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving OS compared to SoC chemotherapy.

José Baselga, Executive Vice President, Oncology R&D said, "We are fully committed to a deep analysis of the vast clinical and biomarker data from this trial to gain further insights to improve Immuno-Oncology approaches for patients with metastatic non-small cell lung cancer."

AstraZeneca plans to submit the full results for presentation at a forthcoming medical meeting.

Imfinzi is also being tested as monotherapy in the Phase III PEARL trial, and in combination with chemotherapy with or without tremelimumab in the Phase III POSEIDON trial. These are part of an extensive late-stage Immuno-Oncology programme in Stage IV NSCLC.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT
>